 |
인쇄하기
취소
|
Yooyoung launches new combination form to treat dyslipidemias
Yooyoung Pharmaceutical said yesterday it has recently launched Pravafenix, SMB’s fixed dose combination drug to treat dyslipidemias, with an exclusive marketing right here.
Approved by the European Commission in April 2011, Pravafenix is a medicine that contains the active substances containing 40 mg pravastatin and 160 mg fenofibrate.
Pravafenix is used in adults at high risk of heart d...
Approved by the European Commission in April 2011, Pravafenix is a medicine that contains the active substances containing 40 mg pravastatin and 160 mg fenofibrate.
Pravafenix is used in adults at high risk of heart d...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.